SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-072481
Filing Date
2022-11-15
Accepted
2022-11-14 18:24:32
Documents
14
Period of Report
2022-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea168520-8k_emmauslife.htm   iXBRL 8-K 26780
2 NOVEMBER 14, 2022 PRESS RELEASE ea168520ex99-1_emmauslife.htm EX-99.1 46126
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3635
  Complete submission text file 0001213900-22-072481.txt   253569

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE emma-20221114.xsd EX-101.SCH 3242
5 XBRL LABEL FILE emma-20221114_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE emma-20221114_pre.xml EX-101.PRE 22369
8 EXTRACTED XBRL INSTANCE DOCUMENT ea168520-8k_emmauslife_htm.xml XML 3291
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

IRS No.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 221388433
SIC: 2834 Pharmaceutical Preparations